These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2085 related items for PubMed ID: 18061335

  • 1. Advances in specific immunotherapy for prostate cancer.
    Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [Abstract] [Full Text] [Related]

  • 2. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C, Sanda MG.
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [Abstract] [Full Text] [Related]

  • 3. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM, Gulley JL, Tsang KY, Schlom J.
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [Abstract] [Full Text] [Related]

  • 4. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K, Roos AK, Pavlenko M, Leder C, Wehrum D, Guevara-Patiño J, Andersen RS, Pisa P.
    Vaccine; 2009 Mar 04; 27(10):1557-65. PubMed ID: 19171173
    [Abstract] [Full Text] [Related]

  • 5. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF, Drake CG.
    Surg Oncol Clin N Am; 2007 Oct 04; 16(4):861-71, x. PubMed ID: 18022549
    [Abstract] [Full Text] [Related]

  • 6. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S, Lee JB, Lee GK, Chang J.
    Prostate; 2009 Jun 15; 69(9):938-48. PubMed ID: 19267351
    [Abstract] [Full Text] [Related]

  • 7. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
    Prikler L, Scandella E, Men Y, Engeler DS, Diener PA, Gillessen S, Ludewig B, Schmid HP.
    Aktuelle Urol; 2004 Aug 15; 35(4):326-30. PubMed ID: 15459874
    [Abstract] [Full Text] [Related]

  • 8. Immunotherapeutics in development for prostate cancer.
    Harzstark AL, Small EJ.
    Oncologist; 2009 Apr 15; 14(4):391-8. PubMed ID: 19342474
    [Abstract] [Full Text] [Related]

  • 9. Antitumor vaccination: where we stand.
    Bocchia M, Bronte V, Colombo MP, De Vincentiis A, Di Nicola M, Forni G, Lanata L, Lemoli RM, Massaia M, Rondelli D, Zanon P, Tura S.
    Haematologica; 2000 Nov 15; 85(11):1172-206. PubMed ID: 11074658
    [Abstract] [Full Text] [Related]

  • 10. [Vaccine therapy of prostate cancer].
    Doehn C, Böhmer T, Sommerauer M, Kausch I, Jocham D.
    Aktuelle Urol; 2005 Sep 15; 36(5):407-16. PubMed ID: 16163603
    [Abstract] [Full Text] [Related]

  • 11. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N, Qin H, Li X, Zhou C, Wang D, Ma W, Lin C, Zhang Y, Wang S, Zhang S.
    Immunol Lett; 2007 Nov 15; 113(2):90-8. PubMed ID: 17913245
    [Abstract] [Full Text] [Related]

  • 12. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J, Diener PA, Prikler L, Fürstenberger G, Cerny T, Schmid U, Ackermann DK, Groettrup M.
    Cancer Res; 2000 Oct 01; 60(19):5522-8. PubMed ID: 11034097
    [Abstract] [Full Text] [Related]

  • 13. DC therapy for prostate cancer.
    Swindle PW, Tepes S, Clements J.
    Cytotherapy; 2004 Oct 01; 6(2):164-71. PubMed ID: 15203993
    [Abstract] [Full Text] [Related]

  • 14. Dendritic cell vaccines for the treatment of prostate cancer.
    Lehrfeld TJ, Lee DI.
    Urol Oncol; 2008 Oct 01; 26(6):576-80. PubMed ID: 18996314
    [Abstract] [Full Text] [Related]

  • 15. Current approaches in ovarian cancer vaccines.
    Reinartz S, Wagner U.
    Minerva Ginecol; 2004 Dec 01; 56(6):515-27. PubMed ID: 15729204
    [Abstract] [Full Text] [Related]

  • 16. The use of dendritic cells in cancer immunotherapy.
    Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, Ballestrero A, Brossart P.
    Crit Rev Oncol Hematol; 2008 Mar 01; 65(3):191-9. PubMed ID: 18055210
    [Abstract] [Full Text] [Related]

  • 17. Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens.
    Turkeri L, Onol FF, Ozyurek M.
    Urol Oncol; 2010 Mar 01; 28(3):290-5. PubMed ID: 19362861
    [Abstract] [Full Text] [Related]

  • 18. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S.
    Prostate; 2003 Sep 15; 57(1):80-92. PubMed ID: 12886526
    [Abstract] [Full Text] [Related]

  • 19. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L, Gray A, Hubby B, Kast WM.
    Cancer Res; 2007 Feb 01; 67(3):1344-51. PubMed ID: 17283172
    [Abstract] [Full Text] [Related]

  • 20. Immunology and immunotherapy approaches for prostate cancer.
    Elkord E.
    Prostate Cancer Prostatic Dis; 2007 Feb 01; 10(3):224-36. PubMed ID: 17420764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 105.